Sign In
Buy BIIB
Biogen Earnings Calls
| Release date | Apr 29, 2026 |
| EPS estimate | $3.05 |
| EPS actual | $3.57 |
| EPS Surprise | 17.05% |
| Revenue estimate | 2.287B |
| Revenue actual | 2.478B |
| Revenue Surprise | 8.35% |
| Release date | Feb 06, 2026 |
| EPS estimate | $1.63 |
| EPS actual | $1.99 |
| EPS Surprise | 22.09% |
| Revenue estimate | 2.203B |
| Revenue actual | 2.279B |
| Revenue Surprise | 3.48% |
| Release date | Oct 30, 2025 |
| EPS estimate | $3.88 |
| EPS actual | $4.81 |
| EPS Surprise | 23.97% |
| Revenue estimate | 2.34B |
| Revenue actual | 2.455B |
| Revenue Surprise | 4.91% |
| Release date | Jul 31, 2025 |
| EPS estimate | $3.90 |
| EPS actual | $5.47 |
| EPS Surprise | 40.26% |
| Revenue estimate | 2.328B |
| Revenue actual | 2.646B |
| Revenue Surprise | 13.63% |
Last 4 Quarters for Biogen
Below you can see how BIIB performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 31, 2025 |
| Price on release | $128.00 |
| EPS estimate | $3.90 |
| EPS actual | $5.47 |
| EPS surprise | 40.26% |
| Date | Price |
|---|---|
| Jul 25, 2025 | $131.52 |
| Jul 28, 2025 | $129.28 |
| Jul 29, 2025 | $127.90 |
| Jul 30, 2025 | $126.64 |
| Jul 31, 2025 | $128.00 |
| Aug 01, 2025 | $131.95 |
| Aug 04, 2025 | $132.20 |
| Aug 05, 2025 | $132.89 |
| Aug 06, 2025 | $129.34 |
| 4 days before | -2.68% |
| 4 days after | 1.05% |
| On release day | 3.09% |
| Change in period | -1.66% |
| Release date | Oct 30, 2025 |
| Price on release | $149.61 |
| EPS estimate | $3.88 |
| EPS actual | $4.81 |
| EPS surprise | 23.97% |
| Date | Price |
|---|---|
| Oct 24, 2025 | $149.89 |
| Oct 27, 2025 | $150.43 |
| Oct 28, 2025 | $149.13 |
| Oct 29, 2025 | $147.86 |
| Oct 30, 2025 | $149.61 |
| Oct 31, 2025 | $154.27 |
| Nov 03, 2025 | $151.44 |
| Nov 04, 2025 | $149.33 |
| Nov 05, 2025 | $153.43 |
| 4 days before | -0.187% |
| 4 days after | 2.55% |
| On release day | 3.11% |
| Change in period | 2.36% |
| Release date | Feb 06, 2026 |
| Price on release | $201.18 |
| EPS estimate | $1.63 |
| EPS actual | $1.99 |
| EPS surprise | 22.09% |
| Date | Price |
|---|---|
| Feb 02, 2026 | $179.09 |
| Feb 03, 2026 | $176.76 |
| Feb 04, 2026 | $185.45 |
| Feb 05, 2026 | $185.36 |
| Feb 06, 2026 | $201.18 |
| Feb 09, 2026 | $193.81 |
| Feb 10, 2026 | $188.99 |
| Feb 11, 2026 | $191.20 |
| Feb 12, 2026 | $195.50 |
| 4 days before | 12.33% |
| 4 days after | -2.82% |
| On release day | -3.66% |
| Change in period | 9.16% |
| Release date | Apr 29, 2026 |
| Price on release | $194.38 |
| EPS estimate | $3.05 |
| EPS actual | $3.57 |
| EPS surprise | 17.05% |
| Date | Price |
|---|---|
| Apr 23, 2026 | $187.88 |
| Apr 24, 2026 | $184.38 |
| Apr 27, 2026 | $180.67 |
| Apr 28, 2026 | $183.38 |
| Apr 29, 2026 | $194.38 |
| Apr 30, 2026 | $189.28 |
| May 01, 2026 | $187.06 |
| May 04, 2026 | $187.21 |
| May 05, 2026 | $189.13 |
| 4 days before | 3.46% |
| 4 days after | -2.70% |
| On release day | -2.62% |
| Change in period | 0.665% |
Biogen Earnings Call Transcript Summary of Q1 2026
Biogen reported a solid Q1 2026: total revenue $2.5B (+2% YoY), GAAP EPS $2.15 (+31% YoY) and non-GAAP EPS $3.57 (+18% YoY). Growth products generated $851M (up 12%), led by strong LEQEMBI uptake ($168M, +74% YoY) and continued SKYCLARYS launch progress. Key commercial drivers: approval and early uptake of high‑dose SPINRAZA, expanding use of blood-based biomarkers for LEQEMBI patient identification, and ex‑U.S. launch momentum (including China). Biogen announced a pending acquisition of Apellis (Syfovre, Empaveli) expected to close in Q2 2026; management expects the deal to be accretive to non‑GAAP EPS in 2027 and to materially bolster near‑ and long‑term growth and therapeutic breadth (immunology, rare disease, ophthalmology, nephrology). Financial position: $4.7B cash & marketable securities, $1.5B net debt; planned funding for Apellis using $3.6B cash + $2.0B bank borrowings (expected to be repaid by end of 2027). R&D and SG&A investments are being maintained to support multiple late‑stage programs (notably felzartamab, litifilimab, salanersen, Zorevunenersen) with a multiyear registrational data flow starting in 2026 and important readouts/PDUFA dates ahead (Leqembi subcutaneous initiation PDUFA May 24, BIIB080 midyear proof‑of‑concept, multiple Phase III readouts 2026–2027). Guidance unchanged from February, but Q2 will include IPR&D charges (~$0.80 EPS impact) and the company will provide pro‑forma 2026 guidance after Apellis close.
